CSIMarket
 


Beyondspring Inc   (BYSI)
Other Ticker:  
 

Cumulative Beyondspring Inc 's Working Capital Ratio for Trailing Twelve Months Period

BYSI's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

BYSI Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Growth -51.49 % -51.49 % -51.49 % -51.49 % 10.09 %
Y / Y Current Assets Growth -48.72 % -48.72 % -48.72 % -48.72 % -33.75 %
Working Capital Ratio for Trailing Twelve Months Period 5.24 5.12 5.05 5 4.96
Total Ranking # 921 # 955 # 1163 # 1231 # 1251
Seq. Current Liabilities Growth 0 % 0 % 0 % -51.49 % 0 %
Seq. Current Assets Growth 0 % 0 % 0 % -48.72 % 0 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2022
On the trailing twelve months basis Current Liabilities decreased faster than Beyondspring Inc 's average Current Assets, this led to increase in in Beyondspring Inc 's Working Capital Ratio for Trailing Twelve Months Period to 5.24, Working Capital Ratio for Trailing Twelve Months Period remained below Beyondspring Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 277 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Beyondspring Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about BYSI
Working Capital Ratio BYSI in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 278
Sector # 507
S&P 500 # 902


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.24 4.74 0.92
(Dec 31 2020)   0




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Immutep Limited  14.16 
Calcimedica Inc   14.14 
Stealth Biotherapeutics Corp  13.99 
Prothena Corporation Public Limited Company  13.97 
Savara Inc   13.94 
Prelude Therapeutics Inc  13.89 
Disc Medicine Inc   13.86 
Xenetic Biosciences Inc   13.76 
Point Biopharma Global Inc   13.76 
Akouos inc   13.69 
Neurogene Inc   13.68 
Biomea Fusion Inc   13.55 
Compass Pathways Plc  13.52 
Viking Therapeutics Inc   13.32 
Genprex Inc   13.27 
Shattuck Labs Inc   13.10 
Bio path Holdings inc   13.02 
Lipocine Inc   12.99 
Pliant Therapeutics Inc   12.92 
Processa Pharmaceuticals Inc   12.79 
Reviva Pharmaceuticals Holdings Inc   12.77 
Acasti Pharma Inc   12.61 
Moonlake Immunotherapeutics  12.56 
Bionomics Limited  12.46 
Rocket Pharmaceuticals Inc   12.46 
Relmada Therapeutics Inc   12.38 
Longboard Pharmaceuticals Inc   12.33 
Advaxis Inc   12.28 
Aldeyra Therapeutics Inc   12.28 
Annexon Inc   12.25 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com